Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy
- PMID: 29064904
- PMCID: PMC6056325
- DOI: 10.1097/SLA.0000000000002573
Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy
Comment on
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313. Ann Surg. 2018. PMID: 28549010 Free PMC article. Clinical Trial.
-
Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy.Ann Surg. 2018 Dec;268(6):e60-e61. doi: 10.1097/SLA.0000000000002572. Ann Surg. 2018. PMID: 29064903 No abstract available.
References
-
- Heil J, Schaefgen B, Sinn P, et al. Can a pathological complete response of breast cancer after neo-adjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer. 2016;69:142–150. - PubMed
-
- Kuerer H. [Accessed 12 October, 2017];Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy [ClinicalTrials.gov web site] Available at: https://clinicaltrials.gov/ct2/show/NCT02945579.
-
- Kuerer HM, Vrancken Peeters M, Rea DW, et al. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol. 2017 Epub ahead of print. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical